Hematologic Malignancies Clinical Trial
Official title:
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity conditioning for subjects age 15-65 years with hematologic malignancies. A maximum of 60 eligible subjects will be enrolled and treated in the trial at approximately 10 centers within the U.S.
All subjects will receive a myeloablative or reduced intensity conditioning regimen, after which they will receive 2 Human Leukocyte Antigen (HLA)-matched or partially matched umbilical cord blood (UCB) units. A total of 40 subjects will receive one ProHema-CB as part of a double CB transplant and an additional 20 subjects will be enrolled as concurrent controls. The determination of which CB unit will be the ProHema-CB unit will be made based primarily upon the degree of HLA match. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
| Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
| Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
| Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 |